JP2010509281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509281A5 JP2010509281A5 JP2009535724A JP2009535724A JP2010509281A5 JP 2010509281 A5 JP2010509281 A5 JP 2010509281A5 JP 2009535724 A JP2009535724 A JP 2009535724A JP 2009535724 A JP2009535724 A JP 2009535724A JP 2010509281 A5 JP2010509281 A5 JP 2010509281A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- triazol
- propyl
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 238000005804 alkylation reaction Methods 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- QPHKZDGGFGGCDJ-UHFFFAOYSA-N 1-[2-(4-phenyltriazol-2-yl)ethyl]azepane Chemical compound C1CCCCCN1CCN(N=1)N=CC=1C1=CC=CC=C1 QPHKZDGGFGGCDJ-UHFFFAOYSA-N 0.000 claims 1
- QODYALOVHNCCKF-UHFFFAOYSA-N 1-[2-(4-phenyltriazol-2-yl)ethyl]piperidine Chemical compound C1CCCCN1CCN(N=1)N=CC=1C1=CC=CC=C1 QODYALOVHNCCKF-UHFFFAOYSA-N 0.000 claims 1
- GNNUFCDGSDJQPE-UHFFFAOYSA-N 1-[2-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCN1CCCCC1 GNNUFCDGSDJQPE-UHFFFAOYSA-N 0.000 claims 1
- FXECWAXRHRBMMG-UHFFFAOYSA-N 1-[3-(4-methyl-5-phenyltriazol-2-yl)propyl]piperidine Chemical compound N1=C(C=2C=CC=CC=2)C(C)=NN1CCCN1CCCCC1 FXECWAXRHRBMMG-UHFFFAOYSA-N 0.000 claims 1
- ZAOFUUGYVOBXKH-UHFFFAOYSA-N 1-[3-(4-phenyltriazol-2-yl)propyl]azepane Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCN1CCCCCC1 ZAOFUUGYVOBXKH-UHFFFAOYSA-N 0.000 claims 1
- ZJCIOJGJGJKZBR-UHFFFAOYSA-N 1-[3-(4-phenyltriazol-2-yl)propyl]piperidine Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCN1CCCCC1 ZJCIOJGJGJKZBR-UHFFFAOYSA-N 0.000 claims 1
- IILGCCWJULTKPO-UHFFFAOYSA-N 1-[3-[4-(2,4-dichlorophenyl)-5-(4-methylphenyl)triazol-2-yl]propyl]piperidine Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=NN1CCCN1CCCCC1 IILGCCWJULTKPO-UHFFFAOYSA-N 0.000 claims 1
- RXMSTAIWAPIJNB-UHFFFAOYSA-N 1-[3-[4-(4-bromo-2-fluorophenyl)triazol-2-yl]propyl]piperidine Chemical compound FC1=CC(Br)=CC=C1C1=NN(CCCN2CCCCC2)N=C1 RXMSTAIWAPIJNB-UHFFFAOYSA-N 0.000 claims 1
- VWKBXKVJNNHWBY-UHFFFAOYSA-N 1-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]-4-phenylpiperazine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCN(C=2C=CC=CC=2)CC1 VWKBXKVJNNHWBY-UHFFFAOYSA-N 0.000 claims 1
- GNBYZIZVAFKIAD-UHFFFAOYSA-N 1-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]-4-phenylpiperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCC(C=2C=CC=CC=2)CC1 GNBYZIZVAFKIAD-UHFFFAOYSA-N 0.000 claims 1
- RXLFBOFHZJXGRZ-UHFFFAOYSA-N 1-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCCCC1 RXLFBOFHZJXGRZ-UHFFFAOYSA-N 0.000 claims 1
- OWXBJIZYYYWPOK-UHFFFAOYSA-N 1-[4-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]butyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCCN1CCCCC1 OWXBJIZYYYWPOK-UHFFFAOYSA-N 0.000 claims 1
- SLLZNMBEIVMVOK-UHFFFAOYSA-N 1-[5-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]pentyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCCCN1CCCCC1 SLLZNMBEIVMVOK-UHFFFAOYSA-N 0.000 claims 1
- PDHJSTSIOUMGPN-UHFFFAOYSA-N 4-[2-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]ethyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCN1CCOCC1 PDHJSTSIOUMGPN-UHFFFAOYSA-N 0.000 claims 1
- MLVGRNXYOQCXIV-UHFFFAOYSA-N 4-[3-(4-phenyltriazol-2-yl)propyl]morpholine Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCN1CCOCC1 MLVGRNXYOQCXIV-UHFFFAOYSA-N 0.000 claims 1
- SMIIMABNEHRULZ-UHFFFAOYSA-N 4-[3-[4-(2,4-dichlorophenyl)-5-(4-methylphenyl)triazol-2-yl]propyl]morpholine Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=NN1CCCN1CCOCC1 SMIIMABNEHRULZ-UHFFFAOYSA-N 0.000 claims 1
- CKRUXDNBPZPWFQ-UHFFFAOYSA-N 4-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCOCC1 CKRUXDNBPZPWFQ-UHFFFAOYSA-N 0.000 claims 1
- -1 4-phenyl-2H- [1,2,3] triazol-2-yl Chemical group 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000006352 cycloaddition reaction Methods 0.000 claims 1
- CGTZBPXNCBEGCF-UHFFFAOYSA-N cyclohexyl-[3-(4-phenyltriazol-2-yl)propyl]azanium;oxalate Chemical compound [O-]C(=O)C([O-])=O.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH2+]C1CCCCC1.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH2+]C1CCCCC1 CGTZBPXNCBEGCF-UHFFFAOYSA-N 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- NIYPGISONFFNHM-UHFFFAOYSA-N n-[3-(4-phenyltriazol-2-yl)propyl]cyclohexanamine Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCNC1CCCCC1 NIYPGISONFFNHM-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- NPBKURVBIBVLQT-UHFFFAOYSA-N oxalate;1-[2-(4-phenyltriazol-2-yl)ethyl]azepan-1-ium Chemical compound [O-]C(=O)C([O-])=O.C1CCCCC[NH+]1CCN(N=1)N=CC=1C1=CC=CC=C1.C1CCCCC[NH+]1CCN(N=1)N=CC=1C1=CC=CC=C1 NPBKURVBIBVLQT-UHFFFAOYSA-N 0.000 claims 1
- YOJDPGSWUXZELU-UHFFFAOYSA-N oxalate;1-[2-(4-phenyltriazol-2-yl)ethyl]piperidin-1-ium Chemical compound [O-]C(=O)C([O-])=O.C1CCCC[NH+]1CCN(N=1)N=CC=1C1=CC=CC=C1.C1CCCC[NH+]1CCN(N=1)N=CC=1C1=CC=CC=C1 YOJDPGSWUXZELU-UHFFFAOYSA-N 0.000 claims 1
- OPWXENSJZGQMSL-UHFFFAOYSA-N oxalate;1-[3-(4-phenyltriazol-2-yl)propyl]azepan-1-ium Chemical compound [O-]C(=O)C([O-])=O.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH+]1CCCCCC1.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH+]1CCCCCC1 OPWXENSJZGQMSL-UHFFFAOYSA-N 0.000 claims 1
- VOARFLHAROLHPP-UHFFFAOYSA-N oxalate;1-[4-(4-phenyltriazol-2-yl)butyl]azepan-1-ium Chemical compound [O-]C(=O)C([O-])=O.C1CCCCC[NH+]1CCCCN(N=1)N=CC=1C1=CC=CC=C1.C1CCCCC[NH+]1CCCCN(N=1)N=CC=1C1=CC=CC=C1 VOARFLHAROLHPP-UHFFFAOYSA-N 0.000 claims 1
- ORLHQGLBCFPLHT-UHFFFAOYSA-N oxalate;4-[3-(4-phenyltriazol-2-yl)propyl]morpholin-4-ium Chemical compound [O-]C(=O)C([O-])=O.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH+]1CCOCC1.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH+]1CCOCC1 ORLHQGLBCFPLHT-UHFFFAOYSA-N 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 C*1C=CC(c2n[n]nc2*)=C*(*)C=C1 Chemical compound C*1C=CC(c2n[n]nc2*)=C*(*)C=C1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380289A EP1921071A1 (en) | 2006-11-10 | 2006-11-10 | 1,2,3- triazole derivatives as sigma receptor inhibitors |
| PCT/EP2007/062010 WO2008055933A1 (en) | 2006-11-10 | 2007-11-07 | 1,2,3-triazole derivatives as sigma receptor inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509281A JP2010509281A (ja) | 2010-03-25 |
| JP2010509281A5 true JP2010509281A5 (enExample) | 2010-12-24 |
Family
ID=37963991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535724A Pending JP2010509281A (ja) | 2006-11-10 | 2007-11-07 | シグマ受容体阻害剤としての１，２，３−トリアゾール誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8193223B2 (enExample) |
| EP (2) | EP1921071A1 (enExample) |
| JP (1) | JP2010509281A (enExample) |
| KR (1) | KR20090087032A (enExample) |
| CN (1) | CN101589029A (enExample) |
| AU (1) | AU2007316606A1 (enExample) |
| BR (1) | BRPI0718586A2 (enExample) |
| CA (1) | CA2668996A1 (enExample) |
| ES (1) | ES2413559T3 (enExample) |
| MX (1) | MX2009004745A (enExample) |
| RU (1) | RU2009122198A (enExample) |
| WO (1) | WO2008055933A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2395003A1 (en) | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2548878A1 (en) * | 2011-07-21 | 2013-01-23 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2752411A1 (en) * | 2013-01-07 | 2014-07-09 | Laboratorios Del Dr. Esteve, S.A. | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders |
| EP2792679A1 (en) * | 2013-04-19 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Tricyclic triazolic compounds |
| EP2989105B1 (en) | 2013-04-23 | 2020-03-11 | Esteve Pharmaceuticals, S.A. | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments |
| MA38569A1 (fr) | 2013-04-23 | 2017-03-31 | Esteve Labor Dr | Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments |
| EP2832720A1 (en) | 2013-07-30 | 2015-02-04 | Laboratorios Del. Dr. Esteve, S.A. | 1,2-disubstituted cyclobutyl compounds |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| MA41177A (fr) * | 2014-12-15 | 2017-10-24 | Esteve Labor Dr | Utilisation de ligands des récepteurs sigma dans l'arthrose |
| HUE058156T2 (hu) | 2015-01-30 | 2022-07-28 | Neurocrine Biosciences Inc | Helyettesített triazolok és ezekkel kapcsolatos eljárások |
| CN106866555B (zh) * | 2017-02-08 | 2019-04-30 | 东南大学 | 1-二苯甲基-4-甲基哌嗪类化合物其制备方法和应用 |
| WO2020123847A1 (en) * | 2018-12-12 | 2020-06-18 | Rutgers, The State University Of New Jersey | Organic compounds |
| CN116178286B (zh) * | 2021-11-26 | 2024-12-03 | 华东师范大学 | 一种n2烷基取代的三氮唑衍生物及其合成方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| AU2002224478A1 (en) * | 2000-11-02 | 2002-05-15 | K And K Biosciences, Inc. | Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke |
| EP1954128A4 (en) * | 2005-11-04 | 2010-09-22 | Merck Sharp & Dohme | DIPHENYLMETHANE DERIVATIVES AS AN INHIBITORS OF THE LEUKOTRIEN BIOSYNTHESIS |
-
2006
- 2006-11-10 EP EP06380289A patent/EP1921071A1/en not_active Withdrawn
-
2007
- 2007-11-07 ES ES07822321T patent/ES2413559T3/es active Active
- 2007-11-07 WO PCT/EP2007/062010 patent/WO2008055933A1/en not_active Ceased
- 2007-11-07 CN CNA2007800418260A patent/CN101589029A/zh active Pending
- 2007-11-07 US US12/514,213 patent/US8193223B2/en not_active Expired - Fee Related
- 2007-11-07 AU AU2007316606A patent/AU2007316606A1/en not_active Abandoned
- 2007-11-07 BR BRPI0718586-3A2A patent/BRPI0718586A2/pt not_active Application Discontinuation
- 2007-11-07 CA CA002668996A patent/CA2668996A1/en not_active Abandoned
- 2007-11-07 EP EP07822321A patent/EP2097392B1/en not_active Not-in-force
- 2007-11-07 KR KR1020097011468A patent/KR20090087032A/ko not_active Withdrawn
- 2007-11-07 RU RU2009122198/04A patent/RU2009122198A/ru not_active Application Discontinuation
- 2007-11-07 JP JP2009535724A patent/JP2010509281A/ja active Pending
- 2007-11-07 MX MX2009004745A patent/MX2009004745A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509281A5 (enExample) | ||
| JP2010509280A5 (enExample) | ||
| RU2009122198A (ru) | Производные 1,2,3-триазола в качестве ингибиторов сигма-рецепторов | |
| RU2009122197A (ru) | Производные 1,2,4-триазолы в качестве ингибиторов сигма-рецептора | |
| DK145644B (da) | Analogifremgangsmaade til fremstilling af imidazolforbindelser | |
| HU220088B (hu) | Tetrahidro-piridin- (vagy -4-hidroxi-piperidin)-alkil-azol-származékok és alkalmazásuk | |
| CN102046610A (zh) | 苯基哌嗪化合物和包含所述化合物的药物组合物及其用途 | |
| JP2016540793A5 (enExample) | ||
| JP2009528319A5 (enExample) | ||
| CN1169798C (zh) | 新型三氮唑醇类抗真菌化合物及其制备方法 | |
| US8772299B2 (en) | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | |
| EP3452467A1 (de) | Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen | |
| JP3782455B2 (ja) | アポリポタンパク質−ｂ合成阻害剤としての新規なトリアゾロン | |
| PT841327E (pt) | Agente anti-fungico de triazole | |
| DE60013515T2 (de) | 4-Arylpiperidinderivate zur Behandlung von Pruritus | |
| CA2249529A1 (en) | New triazoles as therapeutic agents for fungal infections | |
| US4785117A (en) | 5,5-disubstituted-3-phenyl-3-phenyl-3-[(1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl)]-2-methylisoxazolidine derivatives (IR 3012) | |
| US4835283A (en) | 3,5-diphenyl-3-[(1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl)]-2 | |
| US4749793A (en) | 5-substituted-3-phenyl-3-[1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl]-2-benzylisoxazolidines (ir 3011) | |
| EP0310061A1 (en) | 5-Mono or Disubstituted-3-(phenyl or 2-naphthalenyl)-3-[(1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl)]-2-(methyl or benzyl)isoxazolidines | |
| US4831154A (en) | 5-alkyl(or alkenyl)-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | |
| US4767867A (en) | 5-(alkoxyalkyl)-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | |
| JP2005272450A5 (enExample) | ||
| US4777264A (en) | 5-carbonyl derivatives of 3-phenyl-3-(1H-imadazol-1-ylmethyl)-2-methylisoxazolidines and related compounds thereof |